SCHEMBL3709481

SCHEMBL3709481

CC(=O)C1=C(O)C(=O)N(CCc2ccccc2)C1c1ccncc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.66
KDM4E B2RXH2 7/20 0.66
RXFP1 Q9HBX9 3/20 0.66
PPARG P37231 1/20 0.66
NCOA2 Q15596 1/20 0.66
NCOR2 Q9Y618 1/20 0.66
ALOX15 P16050 2/20 0.65
LMNA P02545 1/20 0.65
HPGD P15428 1/20 0.62
POLB P06746 1/20 0.59
MEN1 O00255 2/20 0.57
KMT2A Q03164 2/20 0.57
NPSR1 Q6W5P4 1/20 0.57
TSHR P16473 1/20 0.57
USP2 O75604 1/20 0.56
FPR1 P21462 1/20 0.56
PKM P14618 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
MAPT P10636 1/20 0.55
HTT P42858 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3705035 0.88 KDM4E (0.66) ALDH1A1KDM4ERXFP1ALOX15LMNA
SCHEMBL3709876 0.87 ALDH1A1 (0.74) ALDH1A1KDM4ERXFP1PPARGNCOA2
SCHEMBL3707576 0.86 KDM4E (0.64) ALDH1A1KDM4ERXFP1ALOX15LMNA
SCHEMBL16904821 0.86 KDM4E (0.64) ALDH1A1KDM4ERXFP1ALOX15LMNA
SCHEMBL3704238 0.86 USP7 (0.68) ALDH1A1KDM4ERXFP1PPARGNCOA2
SCHEMBL3705340 0.85 MEN1 (0.78) ALDH1A1KDM4ERXFP1ALOX15LMNA
SCHEMBL3713778 0.85 KDM4E (0.63) ALDH1A1KDM4ERXFP1ALOX15LMNA
SCHEMBL3712661 0.85 KMT2A (0.57) ALDH1A1KDM4ERXFP1PPARGNCOA2
SCHEMBL3709475 0.85 KDM4E (0.59) ALDH1A1KDM4ERXFP1PPARGNCOA2
SCHEMBL15563822 0.84 GRIN2C (0.67) ALDH1A1KDM4EALOX15LMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010081783-A1 NOVEL SPECIFIC INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS HYBRIGENICS SA (FR) 2010-07-22 WO claimed
EP-2208725-A1 Novel specific inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications Hybrigenics S.A. (FR) 2010-07-21 EP claimed
US-20220125760-A1 USE OF USP7 INHIBITORS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) UNIVERSITÉ PAUL SABATIER TOULOUSE III (FR) 2022-04-28 US disclosed
EP-3923987-A1 USE OF USP7 INHIBITORS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) 2021-12-22 EP disclosed
WO-2020165315-A1 USE OF USP7 INHIBITORS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2020-08-20 WO disclosed
WO-2010081783-A1 NOVEL SPECIFIC INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS HYBRIGENICS SA (FR) 2010-07-22 WO disclosed
WO-2010081783-A1 NOVEL SPECIFIC INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS HYBRIGENICS SA (FR) 2010-07-22 WO disclosed
EP-2208725-A1 Novel specific inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications Hybrigenics S.A. (FR) 2010-07-21 EP disclosed
EP-2208725-A1 Novel specific inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications Hybrigenics S.A. (FR) 2010-07-21 EP disclosed